Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label Phase 3 emicizumab prophylaxis trial in hemophilia A with inhibitors
2015-002866-21Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of emicizumab in hemophilia A (2 arms), sponsored by Roche. Primary endpoint: Number of bleeds over time. Started Sep 2015; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2015-002866-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002866-21.